Close
Close

Magic™ Human CD19 MC-38 Cell Line (CAT#: S01YF-0123-KX177)

Datasheet
This product is a MC-38 stable cell line. It stably expresses Human CD19 to provide cell models for research and screening applications.

Product Information

  • Target Protein
  • CD19
  • Target Protein Species
  • Human
  • Accession Number
  • NM_001178098.1
  • Protein Tag
  • Tag-free
  • Host Cell Type
  • MC-38
  • Target Classification
  • CD
  • Target Family
  • CD
  • Target Research Area
  • Autoimmune Research; Immunology Research
  • Related Diseases
  • Immunodeficiency

Product Properties

  • Morphology
  • Fibroblastoid cells growing as a monolayer
  • Assay Types
  • Drug screening and biological assays
  • Resistance
  • Puromycin
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • 10 passages
  • Biosafety Level
  • Level 1
  • Activity
  • Yes
  • Quantity
  • 5x10⁶ cells
  • Form
  • Frozen cells
  • Freeze Medium
  • 70% RPMI 1640 + 20% FBS + 10% DMSO
  • Culture Medium
  • RPMI 1640 + 10% FBS + 5µg/mL Puromycin
  • Selective Antibiotic(s)
  • Regular antibiotics active against mycoplasmas, bacteria and fungi.
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Incubation
  • 37°C with 5% CO₂
  • Applications
  • Drug screening and biological assays
  • Application Notes
  • Cells were plated in a 384-well plate and incubated overnight at 37°C and 5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control for high-throughput drugs screening andfunctional assays.
  • Use Restrictions
  • These cells are distributed for research use only.
  • Shipping
  • Dry ice
  • Storage
  • Liquid nitrogen

Target

  • Full Name
  • CD19 molecule
  • Introduction
  • This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
  • Alternative Names
  • CD19; B4; CVID3; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12; differentiation antigen CD19; CD19 molecule

Customer reviews and Q&As    

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2025 Creative Biolabs. | Contact Us